

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fujian Haixi Pharmaceuticals Co., Ltd.

福建海西新藥創制股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2637)

DISCLOSEABLE TRANSACTION SUBSCRIPTIONS OF FINANCIAL PRODUCTS

SUBSCRIPTIONS OF FINANCIAL PRODUCTS

The Board announces that on 24 October 2025, Fujian Haixi Pharmaceuticals Co., Ltd. (the “**Company**”) as the investor subscribed for (i) HKD200,000,000 of Series 2025-32 Fund Linked Notes (the “**Fund Linked Notes**”) issued by Essence Global Investment Limited under the US\$1,000,000,000 Guaranteed Structured Note Programme (the “**Subscription of Fund Linked Notes**”); and (ii) up to HKD200,000,000 in China Rock Fund SPC (the “**Subscription of China Rock Fund**”, and together with the Subscription of Fund Linked Notes, the “**Subscriptions**”) using its idle funds.

The key terms of the Subscriptions are set out below:

A. Subscription of Fund Linked Notes

No.	Term	Details
1	Subscription Date	24 October 2025
2	Issuer	Essence Global Investment Limited (incorporated in the Cayman Islands)
3	Guarantor	SDIC Securities International Financial Holdings Limited
4	Dealer	SDICS International Securities (Hong Kong) Limited
5	Product Name	Series 2025-32 Fund Linked Notes

No.	Term	Details
6	Principal Amount Subscribed	HKD200,000,000
7	Maturity	a term of three years ending on 27 October 2028
8	Underlying Fund	Generations Capital Management SP, a segregated portfolio of Prudent Wealth Global Fund SPC (incorporated in the Cayman Islands). The Underlying Fund will invest in relatively conservative asset classes such as cash, short term US treasury bills and other instruments to maintain liquidity and manage cash position.
9	Interest Basis	<p>The interest payable is linked to the returns generated by the Underlying Fund. The Issuer will use the proceeds from the issue of these notes to subscribe for the SP1-Class A shares of Generations Capital Management SP in the Underlying Fund (the “Fund Interests”), and any returns received by the Issuer from such Fund Interests will be passed through to the noteholders on a pro-rata basis.</p> <p>The interest payable on each interest payment date shall be calculated as follows:</p> $\text{Interest Payment Amount} = \text{Fund Return Amount} \times (\text{Nominal Amount of Notes held by Noteholder} \div \text{Total Nominal Amount of Notes})$ <p>“Fund Return Amount” means any dividend, distribution, interest, gain, profit or other return of whatsoever nature received by or for the account of the Issuer in respect of the Fund Interests (including, without limitation, any amount received upon any disposal, redemption, repurchase, cancellation or other transfer of the Fund Interests), after deducting therefrom: (i) any costs or expenses properly incurred by the Issuer in connection with managing, maintaining or realising the Fund Interests; and (ii) any taxes, duties or other charges payable by the Issuer in respect of such amounts.</p>

No.	Term	Details
10	Redemption	<p>On the maturity date (27 October 2028), the Issuer shall redeem the notes at the Redemption Amount (see below), subject to the Issuer's ability to dispose of the Fund Interests.</p> <p>The Redemption Amount shall be calculated as follows:</p> <p>Redemption Amount = (realised proceeds of the Fund Interests × (nominal amount of notes ÷ total nominal amount of notes)) - (outstanding management fees + extraordinary expenses)</p>
11	Management Fee	0.30% per annum, deducted from redemption proceeds

B. Subscription of China Rock Fund

No.	Term	Details
1	Subscription Date	24 October 2025
2	Product Name	China Rock Fund SPC (incorporated in the Cayman Islands)
3	Principal Amount Subscribed	Up to HKD200,000,000
4	Expected Annual Return Rate	2.5% - 6.0% (determined based on U.S. Federal Reserve interest rate policy)
5	Type of Product	Principal-protected product (保本產品)
6	Investment Scope	Short-term high-quality money market instruments including U.S. Treasuries with remaining maturity under one year, cash or cash equivalents
7	Redemption	May redeem at any time; redemption application is irrevocable once submitted

BASIS OF DETERMINATION FOR THE CONSIDERATION

The Directors confirmed that the consideration for each of the Subscriptions was determined on the basis of commercial terms negotiated at arm's length between the Group and the respective counterparties, having considered (i) the current available surplus cash of the Group for treasury management purposes; and (ii) the expected investment return and terms of the relevant products.

REASONS FOR AND BENEFITS OF THE SUBSCRIPTIONS

Using temporary idle funds reasonably and effectively will enhance the capital gain of the Company, which is consistent with the core objectives of the Company to ensure capital safety and liquidity and meet the capital needs of the Group's daily operations and dividend payment.

The Directors considered that the terms and the transactions contemplated under the agreements in respect of the Subscriptions are fair and reasonable, on normal commercial terms, and are in the interests of the Company and its Shareholders as a whole.

The Group has implemented adequate and appropriate internal control procedures to ensure the Subscriptions would not affect the working capital or the operations of the Group, and that such investment would be conducted on the principle of protecting the interests of the Company and its Shareholders as a whole.

GENERAL INFORMATION ON THE PARTIES

Information on the Group

The Company is a joint stock company incorporated in the People's Republic of China with limited liability, whose shares are listed on the Main Board of the Stock Exchange. It is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of innovative drug candidates. The Group has a diversified product portfolio and pipeline in the largest and fastest growing therapeutic areas in China.

Information on Essence Global Investment Limited

Essence Global Investment Limited is a company incorporated in the Cayman Islands, which acts as the issuer of the Fund Linked Notes. It is principally engaged in investment banking, asset management, and cross-border financing.

Information on SDICS International Securities (Hong Kong) Limited

SDICS International Securities (Hong Kong) Limited is a company incorporated in Hong Kong, which acts as the dealer and calculation agent in respect of the Fund Linked Notes.

Information on China Rock Fund SPC

China Rock Fund SPC is a segregated portfolio company incorporated in the Cayman Islands. The fund manager of China Rock Fund SPC (the “**Fund Manager**”) is Pamirs Capital (H.K.) Limited, a company incorporated in Hong Kong with limited liability, licensed for Type 1 (Dealing in Securities), Type 4 (Advising on Securities), and Type 9 (Asset Management) regulated activities by the Securities and Futures Commission of Hong Kong. The Fund Manager primarily engages in investment consultancy and asset management. Mr. Lai Chak Ming is the ultimate beneficial owner.

As at the date of this announcement, to the best knowledge and belief of the Directors and having made all reasonable enquiries, each of the above parties and their respective ultimate substantial beneficial owners are independent third parties of the Company and its connected persons.

LISTING RULES IMPLICATIONS

As the highest applicable percentage ratio (as defined under Rule 14.07 of the Listing Rules) in respect of each of the Subscriptions exceeds 5% but is less than 25%, each of the Subscriptions constitutes discloseable transactions of the Company for the purpose of the Listing Rules and is subject to the notification and announcement requirements but is exempt from the shareholders’ approval requirement under Chapter 14 of the Listing Rules.

DEFINITIONS

In this announcement, the following expressions have the meanings set out below, unless the context requires otherwise:

“Board”	the board of directors of the Company
“Company”	Fujian Haixi Pharmaceuticals Co., Ltd. (福建海西新藥創制股份有限公司), a limited liability company incorporated in the PRC on March 27, 2012 and converted into a joint stock company with limited liability on November 15, 2022
“connected person”	has the meaning ascribed thereto in the Listing Rules
“Director(s)”	director(s) of the Company
“Group”	the Company and its subsidiaries

“HKD”	Hong Kong dollars, the lawful currency of the Hong Kong Special Administrative Region of the PRC
“independent third party(ies)”	an individual(s) or a company(ies) who or which, to the best knowledge and belief of the Directors and having made all reasonable enquiries, is(are) not a connected person of the Company within the meaning of the Listing Rules
“Issuer”	Essence Global Investment Limited
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“PRC”	the People’s Republic of China excluding, for the purposes of this announcement, the Hong Kong Special Administrative Region of the PRC, the Macau Special Administrative Region of the PRC and Taiwan
“Shareholder(s)”	shareholder(s) of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Underlying Fund”	Generations Capital Management SP, a segregated portfolio of Prudent Wealth Global Fund SPC
“%”	per cent

By Order of the Board
Fujian Haixi Pharmaceuticals Co., Ltd.
Dr. Kang Xinshan
Chairman and Executive Director

Fujian, the PRC, 5 February 2026

As at the date of this announcement, the executive Directors are Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Dr. Chen Shuyi; the non-executive Directors are Mr. Xu Dong and Mr. Wang Xinkun; and the independent non-executive Directors are Mr. Gong Weimin, Ms. Wang Shan Shan and Ms. Pu Meiting.